The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CPH | +8.11% | +1,448.39% | +72.87% | +289% |
| S&P | +13.95% | +78.35% | +12.25% | +506% |
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. It acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products. Its products include dermatology, hospital acute care, and out-licensed products. The company was founded in 2000 and is headquartered in Mississauga, Canada.
No news articles found for Cipher Pharmaceuticals.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $17.68M | 25.0% |
| Gross Profit | $11.97M | 35.5% |
| Gross Margin | 67.70% | 5.3% |
| Market Cap | $392.84M | 0.7% |
| Net Income | $7.58M | 1862.8% |
| EBITDA | $9.33M | 208.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $11.72M | -8.9% |
| Accounts Receivable | $14.09M | -21.1% |
| Inventory | 9.3 | 31.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $18.28M | -66.6% |
| Short Term Debt | $354.81K | -0.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 11.70% | -1.3% |
| Return On Invested Capital | 21.26% | -0.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $14.93M | 454.3% |
| Operating Free Cash Flow | $14.93M | 448.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 22.21 | 24.76 | 18.99 | 16.40 | -3.54% |
| Price to Book | 2.74 | 2.22 | 2.12 | 2.63 | -13.03% |
| Price to Sales | 8.00 | 6.05 | 5.00 | 5.61 | -47.33% |
| Price to Tangible Book Value | -96.19 | 36.95 | 20.70 | 17.23 | 361.06% |
| Price to Free Cash Flow TTM | 13.72 | 11.33 | 11.30 | 9.43 | -56.49% |
| Enterprise Value to EBITDA | 288.10 | 60.32 | 37.38 | 42.83 | -69.57% |
| Free Cash Flow Yield | 7.3% | 8.8% | 8.8% | 10.6% | 129.84% |
| Return on Equity | 12.5% | 9.7% | 12.5% | 16.6% | -8.44% |
| Total Debt | $58.36M | $58.31M | $34.73M | $18.64M | -66.15% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
